Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial

Luigi Di Biase, J. David Burkhardt, Dhanujaya Lakkireddy, Corrado Carbucicchio, Sanghamitra Mohanty, Prasant Mohanty, Chintan Trivedi, Pasquale Santangeli, Rong Bai, Giovanni Forleo, Rodney Horton, Shane Bailey, Javier Sanchez, Amin Al-Ahmad, Patrick Hranitzky, G. Joseph Gallinghouse, Gemma Pelargonio, Richard H. Hongo, Salwa Beheiry, Steven C. Hao & 7 others Madhu Reddy, Antonio Rossillo, Sakis Themistoclakis, Antonio Dello Russo, Michela Casella, Claudio Tondo, Andrea Natale

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p <0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p <0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)

Original languageEnglish (US)
Pages (from-to)2872-2882
Number of pages11
JournalJournal of the American College of Cardiology
Volume66
Issue number25
DOIs
StatePublished - Dec 29 2015

Fingerprint

Ventricular Tachycardia
Cardiomyopathies
Multicenter Studies
Recurrence
Catheter Ablation
Mortality
Ablation Techniques
Implantable Defibrillators
Anti-Arrhythmia Agents
Cicatrix
Shock

Keywords

  • amiodarone
  • catheter ablation
  • ischemic cardiomyopathy
  • myocardial infarction
  • outcomes
  • ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial. / Di Biase, Luigi; Burkhardt, J. David; Lakkireddy, Dhanujaya; Carbucicchio, Corrado; Mohanty, Sanghamitra; Mohanty, Prasant; Trivedi, Chintan; Santangeli, Pasquale; Bai, Rong; Forleo, Giovanni; Horton, Rodney; Bailey, Shane; Sanchez, Javier; Al-Ahmad, Amin; Hranitzky, Patrick; Gallinghouse, G. Joseph; Pelargonio, Gemma; Hongo, Richard H.; Beheiry, Salwa; Hao, Steven C.; Reddy, Madhu; Rossillo, Antonio; Themistoclakis, Sakis; Dello Russo, Antonio; Casella, Michela; Tondo, Claudio; Natale, Andrea.

In: Journal of the American College of Cardiology, Vol. 66, No. 25, 29.12.2015, p. 2872-2882.

Research output: Contribution to journalArticle

Di Biase, L, Burkhardt, JD, Lakkireddy, D, Carbucicchio, C, Mohanty, S, Mohanty, P, Trivedi, C, Santangeli, P, Bai, R, Forleo, G, Horton, R, Bailey, S, Sanchez, J, Al-Ahmad, A, Hranitzky, P, Gallinghouse, GJ, Pelargonio, G, Hongo, RH, Beheiry, S, Hao, SC, Reddy, M, Rossillo, A, Themistoclakis, S, Dello Russo, A, Casella, M, Tondo, C & Natale, A 2015, 'Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial', Journal of the American College of Cardiology, vol. 66, no. 25, pp. 2872-2882. https://doi.org/10.1016/j.jacc.2015.10.026
Di Biase, Luigi ; Burkhardt, J. David ; Lakkireddy, Dhanujaya ; Carbucicchio, Corrado ; Mohanty, Sanghamitra ; Mohanty, Prasant ; Trivedi, Chintan ; Santangeli, Pasquale ; Bai, Rong ; Forleo, Giovanni ; Horton, Rodney ; Bailey, Shane ; Sanchez, Javier ; Al-Ahmad, Amin ; Hranitzky, Patrick ; Gallinghouse, G. Joseph ; Pelargonio, Gemma ; Hongo, Richard H. ; Beheiry, Salwa ; Hao, Steven C. ; Reddy, Madhu ; Rossillo, Antonio ; Themistoclakis, Sakis ; Dello Russo, Antonio ; Casella, Michela ; Tondo, Claudio ; Natale, Andrea. / Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial. In: Journal of the American College of Cardiology. 2015 ; Vol. 66, No. 25. pp. 2872-2882.
@article{31b0e4ff01b74da3b43fdceebc9fe0c1,
title = "Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial",
abstract = "Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ({"}clinical ablation{"}) versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all {"}abnormal{"} electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5{\%}) and 29 (48.3{\%}) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p <0.001). More patients undergoing clinical VT ablation (58{\%}) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12{\%}; p <0.001). Seven (12{\%}) patients with substrate ablation and 19 (32{\%}) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9{\%}; 8.6{\%} in substrate ablation and 15.0{\%} in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)",
keywords = "amiodarone, catheter ablation, ischemic cardiomyopathy, myocardial infarction, outcomes, ventricular tachycardia",
author = "{Di Biase}, Luigi and Burkhardt, {J. David} and Dhanujaya Lakkireddy and Corrado Carbucicchio and Sanghamitra Mohanty and Prasant Mohanty and Chintan Trivedi and Pasquale Santangeli and Rong Bai and Giovanni Forleo and Rodney Horton and Shane Bailey and Javier Sanchez and Amin Al-Ahmad and Patrick Hranitzky and Gallinghouse, {G. Joseph} and Gemma Pelargonio and Hongo, {Richard H.} and Salwa Beheiry and Hao, {Steven C.} and Madhu Reddy and Antonio Rossillo and Sakis Themistoclakis and {Dello Russo}, Antonio and Michela Casella and Claudio Tondo and Andrea Natale",
year = "2015",
month = "12",
day = "29",
doi = "10.1016/j.jacc.2015.10.026",
language = "English (US)",
volume = "66",
pages = "2872--2882",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "25",

}

TY - JOUR

T1 - Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial

AU - Di Biase, Luigi

AU - Burkhardt, J. David

AU - Lakkireddy, Dhanujaya

AU - Carbucicchio, Corrado

AU - Mohanty, Sanghamitra

AU - Mohanty, Prasant

AU - Trivedi, Chintan

AU - Santangeli, Pasquale

AU - Bai, Rong

AU - Forleo, Giovanni

AU - Horton, Rodney

AU - Bailey, Shane

AU - Sanchez, Javier

AU - Al-Ahmad, Amin

AU - Hranitzky, Patrick

AU - Gallinghouse, G. Joseph

AU - Pelargonio, Gemma

AU - Hongo, Richard H.

AU - Beheiry, Salwa

AU - Hao, Steven C.

AU - Reddy, Madhu

AU - Rossillo, Antonio

AU - Themistoclakis, Sakis

AU - Dello Russo, Antonio

AU - Casella, Michela

AU - Tondo, Claudio

AU - Natale, Andrea

PY - 2015/12/29

Y1 - 2015/12/29

N2 - Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p <0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p <0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)

AB - Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p <0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p <0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)

KW - amiodarone

KW - catheter ablation

KW - ischemic cardiomyopathy

KW - myocardial infarction

KW - outcomes

KW - ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=84955447645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955447645&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2015.10.026

DO - 10.1016/j.jacc.2015.10.026

M3 - Article

VL - 66

SP - 2872

EP - 2882

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 25

ER -